20 articles
A phase II trial explores whether the amino acid L-arginine, with or without enzyme inhibitors, can improve erectile function and quality of life after prostate cancer radiation therapy.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
HIIT training studied in 52 men with prostate cancer on active surveillance to evaluate exercise benefits during watchful waiting.
Small trial tests novel three-drug approach combining immune checkpoint inhibitor, vaccine, and inflammation blocker for metastatic cancers.
First study tests whether supervised exercise training is safe and beneficial for bladder cancer patients during treatment.
A completed pilot trial tested physical therapy and progressive muscle relaxation to preserve function and mood in older adults with advanced lung cancer.
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
Engineered immune cells target CD19+ cancer cells in patients with treatment-resistant lymphoma and leukemia.
A Phase 2 trial testing AR blockade combined with PD-1 inhibition in treatment-emergent neuroendocrine prostate cancer was terminated early.
A phase 2 trial tests obinutuzumab, ibrutinib, and venetoclax in Richter's syndrome, a deadly CLL transformation with few treatment options.
Phase 2 trial explores whether combining oncolytic virus therapy with immunotherapy can rescue patients whose melanoma progressed on PD-1 blockade.
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
A Phase II NCI trial testing bintrafusp alfa in metastatic urothelial carcinoma was terminated after enrolling only 2 patients.
Small trial tests innovative immune cell therapy for patients with relapsed non-Hodgkin's lymphoma who failed standard treatments.
A phase I/II trial tests SV-BR-1-GM, a whole-cell cancer vaccine, combined with the checkpoint inhibitor retifanlimab in patients with metastatic breast cancer.
Genetically modified immune cells target blood cancer that stopped responding to standard treatments in 28-patient trial.
Innovative immunotherapy approach converts patient tumor cells into personalized vaccines to fight aggressive brain cancer.
Researchers tracked immune changes during intensive radiation treatment to optimize cancer therapy and potential immunotherapy combinations.
A pilot trial tested a comprehensive physical, mental, and spiritual intervention for cancer survivors, tracking outcomes at 6 months post-program.
A completed trial examines how structured exercise reshapes body composition and sustains physical activity habits in breast cancer patients post-diagnosis.
